Real-world effectiveness of add-on fremanezumab in patients receiving onabotulinumtoxinA for chronic migraine in a US tertiary headache center

被引：0

作者：

Cohen, Fred ^{[1
]}

Yuan, Hsiangkuo ^{[1
]}

Dent, Kathryn ^{[1
]}

Beucherie, Matthew ^{[1
]}

Connolly, William ^{[1
]}

Driessen, Maurice ^{[2
]}

Krasenbaum, Lynda J. ^{[3
]}

Carr, Karen ^{[4
]}

Hopkins, Mary ^{[1
]}

Marmura, Michael ^{[1
]}

机构：

[1] Thomas Jefferson Univ, Dept Neurol, Jefferson Headache Ctr, Philadelphia, PA USA

[2] Teva Netherlands BV, Global Med Affairs, Amsterdam, Netherlands

[3] Teva Branded Pharmaceut Prod R&D Inc, Global Med Affiars, W Chester, PA USA

[4] US Med Affairs, Teva Pharmaceut, Parsippany, NJ USA

来源：

CEPHALALGIA | 2022年 / 42卷 / 1_SUPPL期

关键词：

D O I：

暂无

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

MTIS22-LBA

引用

页码：127 / 128

页数：2

共 50 条

[31] A single-center retrospective study of onabotulinumtoxinA for treatment of 245 chronic migraine patients: survey results of a real-world experience
Dikmen, Pinar Yalinay
Kosak, Seda
Aydinlar, Elif Ilgaz
Kocaman, Ayse Sagduyu
ACTA NEUROLOGICA BELGICA, 2018, 118 (03) : 475 - 484
[32] Real-world data on quarterly and monthly fremanezumab for reducing migraine days and headache days in US adult patients with migraine: Results from a physician chart review study
Cohen, J. M.
Thompson, S. F.
Ayyagari, R.
Driessen, M. T.
Seminerio, M. J.
Carr, K.
Yim, E.
HEADACHE, 2021, 61 : 69 - 70
[33] REDUCTIONS IN MIGRAINE AND HEADACHE DAYS AFTER INITIATING FREMANEZUMAB FOR PATIENTS WITH MIGRAINE AND PRIOR USE OF ANOTHER MONOCLONAL ANTIBODY TARGETING THE CGRP PATHWAY IN A US REAL-WORLD SETTING
Driessen, M.
Patterson-Lomba, O.
Mu, F.
Thompson, S.
Seminerio, M.
Carr, K.
Sun, R.
Totev, T.
Yim, E.
Ayyagari, R.
Cohen, J.
VALUE IN HEALTH, 2022, 25 (01) : S23 - S23
[34] Real-World Evidence for Control of Chronic Migraine Patients Receiving CGRP Monoclonal Antibody Therapy Added to OnabotulinumtoxinA: A Retrospective Chart Review
Andrew M. Blumenfeld
Benjamin M. Frishberg
Jack D. Schim
Ashley Iannone
Gary Schneider
Larisa Yedigarova
Aubrey Manack Adams
Pain and Therapy, 2021, 10 : 809 - 826
[35] Real-World Evidence for Control of Chronic Migraine Patients Receiving CGRP Monoclonal Antibody Therapy Added to OnabotulinumtoxinA: A Retrospective Chart Review
Blumenfeld, Andrew M.
Frishberg, Benjamin M.
Schim, Jack D.
Iannone, Ashley
Schneider, Gary
Yedigarova, Larisa
Manack Adams, Aubrey
PAIN AND THERAPY, 2021, 10 (02) : 809 - 826
[36] US Real-world Migraine-related Health Care Resource Utilization and Costs for Patients Initiating Fremanezumab
Seminerio, Michael
Tangirala, Krishna
Thompson, Stephen F.
Ariely, Rinat
Cohen, Joshua M.
Carr, Karen
Buse, Dawn C.
NEUROLOGY, 2021, 96 (15)
[37] Real-world evidence of the effectiveness and satisfaction with eptinezumab treatment in patients with chronic migraine
Argoff, C.
Khan, F.
Herzog, S.
Smith, R.
Kotak, S.
Sopina, L.
Soni-Brahmbhatt, S.
Kymes, S.
HEADACHE, 2023, 63 : 160 - 161
[38] Real-World Retrospective Safety Analysis of OnabotulinumtoxinA for the Treatment of Patients with Concurrent Cervical Dystonia and Chronic Migraine
Rhyne, C.
Martinez, K.
Stoilova, J.
Patel, A.
Ifantides, K. Becker
Singh, R.
Yushmanova, I.
Sadeghi, M.
Battucci, S.
Forde, G.
MOVEMENT DISORDERS, 2023, 38 : S350 - S351
[39] Real-world Retrospective Safety Analysis of OnabotulinumtoxinA for the Treatment of Patients With Concurrent Cervical Dystonia and Chronic Migraine
Rhyne, Christopher
Martinez, Kenneth
Stoilova, Juliana
Patel, Atul
Ifantides, Kim Becker
Singh, Ritu
Yushmanova, Irina
Sadeghi, Marjan
Battucci, Simona
Grace, Forde
TOXICON, 2024, 237 : 73 - 74
[40] One year outcome of fremanezumab in refractory chronic migraine patients: Real-world data from the Hull Migraine Clinic, UK
Nasergivehchi, Somayeh
Cheng, Fan
Hussain, Mariam
Khalil, Modar
Ahmed, Fayyaz
CEPHALALGIA, 2022, 42 (1_SUPPL) : 130 - 130

← 1 2 3 4 5 →